Fore Pharmas latest report ‘Global Muscular Dystrophy Drug Pipeline Capsule – 2011 is an outline of all the key research and development (R&D) activities of the global muscular dystrophy drug market. It covers information on key pipeline molecules in various stages of R&D including all the phases of clinical trials, preclinical research, and drug discovery. The report is up-to-date with full coverage of the licensing activities and partnerships.

This report helps executives to keep a track of their competitors and understand their pipeline molecules. The information presented in this report can be used for identifying the partners, prioritizing, evaluating opportunities, developing business development strategies, and executing in-licensing and out-licensing deals.

The report provides information on pipeline molecules by company and mechanism of action across the different stages of R&D. It includes registered / preregistered stage, phase 3 clinical trial, phase 2 clinical trial, phase 1 clinical trial, preclinical research, and drug discovery. It also provides information on pipeline molecules developed in leading geographies including the U.S., Canada, France, Germany, U.K., Italy, and Spain by various stages of R&D. Licensing activities and partnerships in the muscular dystrophy drug market is thoroughly covered by company and licensee with the deal summary.

Key Features of the Report:
- Muscular Dystrophy: Overview
- Muscular Dystrophy Drug Pipeline Overview
- Muscular Dystrophy Phase 3 Clinical Trial Drug Pipeline Insights
- Muscular Dystrophy Phase 2 Clinical Trial Drug Pipeline Insights
- Muscular Dystrophy Phase 1 Clinical Trial Drug Pipeline Insights
- Muscular Dystrophy Preclinical Research Drug Pipeline Insights
- Muscular Dystrophy Drug Discovery Pipeline Insights
- Geographic Landscape of Muscular Dystrophy R&D Activities
- Muscular Dystrophy R&D Activities in North America
- Muscular Dystrophy R&D Activities in Europe
- Licensing Activities / Partnerships in the Global Muscular Dystrophy Drug Market

1. Muscular Dystrophy: Disease Definition
2. Muscular Dystrophy Drug Pipeline Overview
3. Muscular Dystrophy Phase 3 Clinical Trial Drug Pipeline Insights
4. Muscular Dystrophy Phase 2 Clinical Trial Drug Pipeline Insights
5. Muscular Dystrophy Phase 1 Clinical Trial Drug Pipeline Insights
6. Muscular Dystrophy Preclinical Research Drug Pipeline Insights
7. Muscular Dystrophy Drug Discovery Pipeline Insights
8. Geographic Landscape of Muscular Dystrophy R&D Activities
8.1 Muscular Dystrophy R&D Activities in North America
8.2 Muscular Dystrophy R&D Activities in Europe
9 Licensing Activities / Partnerships in the Global Muscular Dystrophy Drug Market
10 Research Methodology Table 1: Muscular Dystrophy Drug Pipeline: Phase 3 Clinical Trial

Table 2: Muscular Dystrophy Drug Pipeline: Phase 2 Clinical Trial
Table 3: Muscular Dystrophy Drug Pipeline: Phase 1 Molecules
Table 4: Muscular Dystrophy Drug Pipeline: Preclinical Research
Table 5: Muscular Dystrophy R&D Activities by Geography
Table 6: Muscular Dystrophy Drug Pipeline: North America
Table 7: Muscular Dystrophy Drug Pipeline: Europe
Table 8: Muscular Dystrophy Drug Pipeline: Licensing Activities

Figure 1 : Muscular Dystrophy Drug Pipeline Molecules by Stages
Figure 2 : Muscular Dystrophy R&D Activities by Geography